The physical form of BPC 157 is white or off-white powder. Its solubility at 25℃ is as follows: water solubility reaches 100 mg/mL (70.44 mM), 50 mg/mL (35.22 mM) in dimethyl sulfoxide (DMSO), and 12 mg/mL (8.45 mM) in ethanol. These characteristics provide an important basis for the development of its preparations.
The manufacturing of BPC 157 Tablets involves complex chemical synthesis, formulation preparation and quality control processes. To ensure product quality and safety, manufacturers must strictly abide by GMP requirements and establish a complete quality management system and risk management plan. Although BPC 157 is currently mainly used for scientific research purposes, with the deepening of research, its potential in clinical applications is worth looking forward to. In the future, manufacturers need to continuously monitor regulatory developments and market demands to promote their research and development as well as industrialization processes.
|
|
|
BPC-157 Powder COA
Chemical Structure and Basic Characteristics of BPC 157
BPC 157 (Body Protection Compound 157) is a synthetic fifteenpeptide with the chemical formula C₆₂H₉₈N₁₆O₂₂, a molecular weight of 1419.54, and a CAS registry number of 137525-51-0. This compound was initially isolated and synthesized from human gastric juice, and its core sequence is a partial fragment of the human gastric juice protein BPC. As a stable gastrin, BPC 157 has deep cell-protective activity, can exert biological effects without a carrier, and can stably exist in gastric juice for more than 24 hours, showing good oral bioavailability.
The physical form of BPC 157 is white or off-white powder. Its solubility at 25℃ is as follows: water solubility reaches 100 mg/mL (70.44 mM), 50 mg/mL (35.22 mM) in dimethyl sulfoxide (DMSO), and 12 mg/mL (8.45 mM) in ethanol. These characteristics provide an important basis for the development of its preparations.
Manufacturing Process and Quality Control
Raw material synthesis
The synthesis of BPC 157 usually adopts the solid-phase peptide synthesis method (SPPS), and the target peptide chain is constructed by gradually adding amino acid residues. This process requires strict control of reaction conditions, including temperature, pH value and solvent selection, to ensure the purity of the product. After the synthesis is completed, it needs to be purified by high performance liquid chromatography (HPLC) to remove impurities and unreacted intermediates.
Preparation of preparations
The preparation of BPC 157 Tablets involves mixing the purified active ingredients with excipients and making tablets through wet granulation or direct tablet pressing processes. The selection of excipients should take into account solubility, stability and bioavailability. Common excipients include microcrystalline cellulose, lactose and magnesium stearate. To ensure product quality, strict tests should be conducted on the hardness, disintegration time limit and content uniformity of the tablets during the formulation process.
Quality control
Quality control runs through the entire process of the tablet production.The chemical structure of the raw materials needs to be confirmed through techniques such as nuclear magnetic resonance (NMR) and mass spectrometry (MS). The preparation shall meet the dissolution rate, content and microbial limit standards stipulated in the pharmacopoeia. In addition, stability testing is an important part of quality control. Through accelerated testing and long-term sample retention observation, the degradation of the product under high temperature and high humidity conditions is evaluated to ensure the stability of its quality within the validity period.
Production Environment and Equipment Requirements
Production environment
The production of BPC 157 Tablets needs to be carried out in a clean workshop that complies with GMP (Good Manufacturing Practice for Pharmaceuticals). The workshop needs to meet the D-level clean standard, and the air cleanliness should be controlled so that the number of dust particles ≥0.5μm in each cubic meter of air does not exceed 3,520,000. During the production process, temperature and humidity must be strictly controlled. The temperature is usually maintained at 18-26℃, and the relative humidity is controlled at 45%-65% to prevent raw materials from absorbing moisture or degrading.
Production equipment
The key production equipment includes solid-phase synthesizers, high-performance liquid chromatographs, tablet presses and coating machines. The solid-phase synthesizer needs to have precise flow control and temperature regulation functions to ensure the accuracy of peptide chain synthesis. The HPLC system needs to be equipped with a highly sensitive ultraviolet detector for real-time monitoring of the purification process. The tablet press should be equipped with pressure regulation and speed control functions to ensure that the hardness and weight differences of the tablets meet the standards.
Packaging and Storage Conditions
Packaging materials
The packaging of BPC 157 Tablets should have the functions of moisture-proofing, light-blocking and oxygen barrier. Common packaging materials include aluminum-plastic blister packaging and high-density polyethylene bottles. Aluminum-plastic blister packaging can effectively prevent tablets from getting damp and mechanically damaged, while high-density polyethylene bottles need to be equipped with desiccants and light-blocking coatings to ensure the stability of the products during storage.
Storage conditions
According to the results of the stability test, this tablet needs to be frozen and stored at -20℃ to slow down its degradation rate.Under these conditions, the validity period of the product can be as long as three years. If transportation is required at room temperature, it is recommended to use ice packs or refrigerated containers to ensure that the product temperature does not exceed 8℃ during transportation and the storage time does not exceed two weeks.
Manufacturers and Supply Chain Management
Main manufacturer
At present, the production of this tablet is mainly concentrated in pharmaceutical enterprises with peptide synthesis technology.For example, a certain technology company in Hangzhou, a certain technology company in Hubei and a certain biomedical technology company in Nanjing, etc., all have the R&D and production capabilities of BPC 157. These enterprises usually have ISO 9001 quality management system certification and are equipped with professional R&D teams and production facilities.
Supply chain management
The supply chain of this tablet involves multiple links such as raw material procurement, production and processing, quality inspection, and logistics distribution. To ensure product quality, manufacturers need to conduct strict audits of raw material suppliers to ensure that they have GMP certification and a quality assurance system. In addition, temperature control equipment should be used during the logistics and distribution process to ensure the temperature stability of the products during transportation.
Regulations and Compliance Requirements
Regulatory supervision
At present, BPC 157 has not yet been approved by mainstream drug regulatory agencies such as the FDA and EMA, and its production and sales are strictly restricted. In most countries and regions, BPC 157 is regarded as an investigational drug or an unapproved drug and is only permitted for scientific research purposes. Manufacturers must comply with relevant regulations to ensure that the products are not used for human treatment.
Compliance requirements
To ensure compliance, manufacturers need to establish a complete quality management system, covering the entire process from raw material procurement, production processing, quality inspection to after-sales service. In addition, manufacturers need to undergo regular audits by regulatory authorities to ensure that their production facilities and quality management systems comply with GMP requirements.
Safety and Risk Management
Safety assessment
Although animal experiments have shown that BPC 157 has good tolerance, its safety in humans has not been fully verified. The manufacturer must clearly state in the product manual that "for research use only, not for human treatment", and remind users to be aware of potential risks.
Risk management
Manufacturers need to establish a risk management plan to identify and assess potential risks in the production process, such as raw material contamination, equipment failure and human operational errors, etc. By formulating emergency plans and conducting regular training, the possibility of risks occurring can be reduced. In addition, manufacturers need to establish a product traceability system to ensure that products can be recalled promptly when quality problems occur.
Current Market Situation and Future Trends
Current market situation
At present, this tablet is mainly targeted at scientific research institutions and biotechnology companies, and is used for research in fields such as inflammatory bowel disease, multiple sclerosis, and wound healing.As it has not obtained drug approval, the market size is relatively small, but the demand is on the rise.
Future trend
With the in-depth research, the potential of BPC 157 in clinical applications has gradually emerged. In the future, if its safety and efficacy are further verified, it may obtain drug approval, thereby promoting the expansion of the market size. Furthermore, advancements in formulation technologies, such as the application of nanocarriers and sustained-release and controlled-release technologies, may enhance the bioavailability and efficacy of BPC 157, providing more possibilities for its clinical application.
Optimization analysis of drug delivery system
As a gastric 15-peptide with biological activities such as anti-ulcer, anti-inflammation and neuroprotection, the optimization of the drug delivery system of BPC 157 is crucial for improving its bioavailability, efficacy and safety. The following discusses the optimization direction of the drug delivery system of BPC 157 Tablets from aspects such as the type of delivery system, the selection of carrier materials, the targeting strategy and the optimization of controlled-release performance.
Selection of Delivery System Type
Drug delivery systems can be classified into physical, chemical and biological delivery systems. In view of the characteristics and therapeutic requirements of BPC 157, chemical delivery systems (such as nano-delivery systems and delivery carriers) and biological delivery systems (such as peptide delivery systems) have significant advantages. Nanoparticles, as drug carriers, are widely used in delivery systems. By adjusting their surface chemical properties and morphology, more efficient targeted drug delivery can be achieved.
Selection of Carrier Materials
Nanoparticles: As carriers, nanoparticles can significantly enhance the bioavailability and delivery efficiency of drugs. By altering the structure and size of nanoparticles, the controlled-release property of drugs can be regulated, achieving precise controlled release of drugs in the body. For instance, by using ph-sensitive or temperature-sensitive materials, drugs can be released under specific conditions, thereby enhancing the therapeutic effect.
Liposomes: Liposomes have high biocompatibility and degradability, and their surfaces can be chemically modified to enhance targeting. For BPC 157, liposome carriers can prolong the retention time of drugs at the lesion site and achieve precise treatment.
Hydrogels: Hydrogels have excellent biocompatibility and drug loading capacity, and can be used to achieve sustained and controlled release of drugs. For patients requiring long-term treatment, hydrogel carriers can provide continuous drug release and reduce the frequency of administration.
Optimization of Targeted Strategies
Surface modification: By adjusting the surface properties of the drug carrier, such as increasing the surface density of the targeting ligand or changing the charge properties on the carrier surface, the targeting ability of BPC 157 can be improved. For instance, by leveraging immunomagnetism or the interaction between specific proteins and lipids, drugs can be guided to specifically target specific cells or tissues.
High-affinity targeting: By using high-affinity targeting covalent bonding and other technologies, the targeting property of drug carriers can be further enhanced. This helps to reduce the side effects of the drug on non-target organs and improve the therapeutic effect.
Controlled-release Optimization
Physicochemical property regulation
By adjusting the physicochemical properties of the drug and the carrier, such as the intermolecular interaction forces and the porosity of the carrier material, the controlled release of the drug can be achieved. For instance, the swelling property of ph-sensitive polymers in acidic environments can be utilized to promote the release of drugs.
Structural design
Design delivery systems with specific structures and morphologies, such as multilayer nanoparticles or core-shell structured microspheres, to achieve pulsed or targeted drug release. This helps to precisely control the release rate and timing of the drug according to the treatment needs.
Intelligent material application
By combining temperature-sensitive materials or ph-sensitive materials and other intelligent materials, a controllable release system that responds to biological signals can be developed. For example, by using changes in body temperature to trigger the release of drugs, personalized disease treatment can be achieved.
BPC-157 tablets represent a paradox: a compound with extraordinary preclinical potential yet mired in regulatory uncertainty. Its ability to heal tissues across systems-from gut ulcers to torn tendons-offers hope to millions suffering from chronic conditions. However, the lack of human safety data, economic disincentives, and doping controversies underscore the challenges ahead. As research progresses, collaboration between academia, industry, and regulators will be critical to unlocking BPC-157's full therapeutic promise while ensuring patient safety. For now, it remains a tantalizing glimpse into the future of regenerative medicine-a peptide on the precipice of transformation.
Frequently Asked Questions
Is BPC-157 effective in pill form?
+
-
Patient Demand and Reported Benefits: Patients have reported positive outcomes using oral BPC 157, particularly in areas like accelerated healing and inflammation reduction.
How much BPC-157 to take orally?
+
-
Typical Dosage Ranges for Different Uses
For general healing and injury recovery, typical dosages range from 200 to 500 micrograms per day, often administered via injection or oral routes. For muscle and joint injuries, doses usually fall between 250 and 500 micrograms, often split into multiple administrations daily.
What are the side effects of BPC-157?
+
-
It is important to acknowledge that many anonymous online users of BPC-157 report adverse effects, including injection site pain and swelling, joint pain, anxiety, panic attacks, heart palpitations, insomnia, drowsiness, weakness, fatigue, loss of appetite, depression, and anhedonia.
Hot Tags: bpc 157 tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 3 bromo 2 chloro 9 9 diphenyl 9H fluorene, iptg powder, 6 methoxyquinolin 7 yl boronic acid, raloxifene powder, N5 dibenzo b d thiophen 3 yl 7 7 dimethyl N5 N9 N9 triphenyl 7H benzo c fluorene 5 9 diamine, 3 bromobenzo b naphtho 2 3 d thiophene